title: [Vaccinations in recurrent urinary tract infections--an observation study relating to health economy].
abstract: OBJECTIVE
  Urinary tract infection (UTI) is one of the most common bacterial infections in women. Despite the need for therapy alter-natives only the conventional treatment using antibiotics is investigated in the literature. A vaccination, however, can be a useful medical and economic alternative for the treatment of recurrent urinary tract infections.
  
  
  METHODS
  An open, prospective, not-randomised, multicentric observation study was carried out to determine the costs and effects of a vaccination in 842 patients with recurrent urinary tract infections. The data for efficacy, safety and costs of recurrent urinary tract infections were collected via patient documentation and a standardised documentation of the physicians.
  
  
  RESULTS
  The efficacy was rated as good to very good by 82.7 % of the physicians and 82.1 % of the patients. The values for safety show even better results. They were rated as good to very good by 92.4 % of the physicians and 90.9 % of the patients. The total costs amounted to 433 euro per patient in the six months before vaccination and decreased significantly to 238 euro in the six months after vaccination (p < 0.0001).
  
  
  CONCLUSIONS
  The results of this observation study show a clinically relevant reduction of recurrent urinary tract infections with acceptable side effects in the six months after vaccination. As the treatment costs are reduced from a mean of 238 euro to 91 euro per patient. The healthcare insurances can also benefit from the vaccination against recurrent urinary tract infections.
authors.affiliation: Privatpraxis für Urologie und Andrologie, Gesundheitszentrum Blütenhof-Berlin, Berlin. info@urologie-lenk.de
authors.forename: Volker Severin
authors.initials: VS
authors.lastname: Lenk
authors.forename: B
authors.initials: B
authors.lastname: Dorsch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007117:Immunization, Secondary / Q000191:economics; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000191:economics* / Q000382:microbiology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics*; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000191:economics*; D055815:Young Adult
chemical_list: D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated